Evidence map›Paper›PMID 33043254›Full record

ArticleNorthern clinics of Istanbul2020

The effects of resveratrol treatment on caveolin-3 expression and Na

Ahmet Ozer Sehirli, Asli Aykac, Sermin Tetik, Omer Yiginer, Sule Cetinel, Naziye Ozkan, Mustafa Akkiprik, Zehra Kaya, Berrak Caglayan Yegen, Mehmet Tezcan and 1 more

Abstract read
In one paragraph

Article in Northern clinics of Istanbul, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Role of NaInternational journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ahmet Ozer SehirliDepartment of Pharmacology, Near East University Faculty of Dentistry, Nicosia, Cyprus.
Asli AykacDepartment of Biophysics, Near East University Faculty of Medicine, Nicosia, Cyprus.
Sermin TetikDepartment of Biochemistry, Marmara University Faculty of Pharmacy, Istanbul, Turkey.
Omer YiginerDepartment of Cardiology, Bahcesehir University, Istanbul, Turkey.
Sule CetinelDepartment of Histology-Embryology, Marmara University Faculty of Medicine, Istanbul, Turkey.
Naziye OzkanDepartment of Histology-Embryology, Marmara University Faculty of Medicine, Istanbul, Turkey.
Mustafa AkkiprikDepartment of Medical Biology, Marmara University Faculty of Medicine, Istanbul, Turkey.
Zehra KayaDepartment of Medical Biology, Marmara University Faculty of Medicine, Istanbul, Turkey.
Berrak Caglayan YegenDepartment of Cardiology, Eskisehir City Hospital, Eskisehir, Turkey.
Mehmet TezcanDepartment of Cardiology, Eskisehir City Hospital, Eskisehir, Turkey.
Göksel SenerDepartment of Pharmacology, Marmara University Faculty of Pharmacy, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe present study aims to investigate the therapeutic effects of resveratrol (RES) on isoproterenol (ISO) induced myocardial injury rat model.

methodsCatecholamine-induced heart damage was induced by ISO treatment for 30 days. The rats were divided into four groups as follows: the control group received saline, the ISO group received 5.0 mg/kg ISO, the RES group received 10 mg/kg RES, and the ISO-RES group received 10 mg/kg RES and 5 mg/kg ISO treatments for 30 days. Following echocardiographic measurements and body weight recorded, the rats were decapitated. Plasma and cardiac tissue samples obtained by decapitation were analyzed using biochemical, histopathological, molecular and immunohistochemical methods.

resultsIn the ISO group, Na

conclusionRES treatment has ameliorated all the functional and biochemical parameters. The results obtained in this study suggest that RES is a promising supplement against catecholamine exposure as it improves antioxidant defense mechanisms in the heart. In the light of above-mentioned data, RES can be assumed as a promising agent in ameliorating the oxidative injury of the myocardium.

Indexed as

Caveolin-3heart failureisoproterenollysosomal enzymesresveratrol

Identifiers

PMID33043254
PMCPMC7521088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.